{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:13:27Z","timestamp":1790230407039,"version":"4.1.0"},"reference-count":69,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Janssen-Cilag Ltd"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Ibrutinib is indicated in Europe for the treatment of several B\u2010cell malignancies, including chronic lymphocytic leukaemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>). However, despite the high efficacy and favourable toxicity profile of ibrutinib, recent data suggest that it is not always administered optimally in clinical practice, with an increased tendency for dose reduction and a higher frequency of discontinuation. An expert panel of European haematologists was convened to identify practical issues pertinent to physicians involved in the therapeutic management of ibrutinib\u2010treated <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> patients and here we outline the findings. Practical management recommendations are given for treating patients with ibrutinib and clinical considerations for the management of adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) that can be associated with ibrutinib treatment are addressed. This article highlights that patients should be monitored for treatment emergent adverse events, most of which are mild, transient and generally occur early in therapy and that, even with more challenging <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s, patients can often be maintained on therapy with minimal disruption through careful management. The necessity to use the correct ibrutinib dose, along with increased awareness, vigilance, mitigation and management of <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s, are all recommended to maximise outcomes for <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> patients treated with ibrutinib.<\/jats:p>","DOI":"10.1111\/bjh.15080","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T14:04:04Z","timestamp":1515593044000},"page":"666-679","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice"],"prefix":"10.1111","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-7430","authenticated-orcid":false,"given":"John G.","family":"Gribben","sequence":"first","affiliation":[{"name":"Barts Cancer Institute Queen Mary University of London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[{"name":"Department of Haematology Vall d'Hebron University Hospital Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cymbalista","sequence":"additional","affiliation":[{"name":"U978 Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Bobigny France"},{"name":"Labex Inflamex Universit\u00e9 Paris 13 Sorbonne Paris Cit\u00e9 Bobigny France"},{"name":"H\u00f4pital Avicenne Assistance Publique\u2013H\u00f4pitaux de Paris Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"Strategic Research Programme on CLL IRCCS San Raffaele Hospital Milan Italy"},{"name":"Universit\u00e0 Vita\u2010Salute San Raffaele Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[{"name":"St James' Institute of Oncology University of Leeds Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital de la Santa Creu Sant Pau Autonomous University of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III University of Ulm Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-722991"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.03.011"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.977862"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.V128.22.234.234","article-title":"Updated efficacy and safety from the phase 3 RESONATE\u20102 study: ibrutinib as first\u2010line treatment option in patients 65 years and older with chronic lymphocytic leukemia\/small lymphocytic leukemia","volume":"128","author":"Barr P.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-737346"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.10.946"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171041"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001883"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1315115"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double\u2010blind, phase 3 study","volume":"17","author":"Chanan\u2010Khan A.","year":"2017","journal-title":"The Lancet Oncology"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood.V128.22.4383.4383","article-title":"Integrated and long\u2010term safety analysis of ibrutinib in patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"128","author":"Coutre S.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle\u2010cell lymphoma: an international, randomised, open\u2010label, phase 3 study","volume":"387","author":"Dreyling M.","year":"2017","journal-title":"The Lancet"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"v143","DOI":"10.1093\/annonc\/mdw359","article-title":"Appendix\u00a06: chronic lymphocytic leukaemia: eUpdate published online September 2016","volume":"27","author":"Eichhorst B.","year":"2016","journal-title":"Annals of Oncology"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14700"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"e2016011","DOI":"10.4084\/mjhid.2016.011","article-title":"BCR signaling inhibitors: an overview of toxicities associated with ibrutinib and idelalisib in patients with chronic lymphocytic leukemia","volume":"8","author":"Falchi L.","year":"2016","journal-title":"Mediterranean Journal of Hematology and Infectious Diseases"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1251592"},{"key":"e_1_2_8_24_1","unstructured":"Fraser G. Cramer P. Demirkan F. Silva R.S. Grosicki S. Janssens A. Mayer J. Dilhuydy M.\u2010S. Pylypenko H. Loscertales J. Goy A. Avigdor A. Rule S. Phelps C. Mahler M. Salman M. Howes A.&Hallek M.(2016)Ibrutinib Plus Bendamustine and Rituximab in Previously Treated CLL\/SLL: 2\u2010Year Follow\u2010up Including MRD From the HELIOS Study. Available at:https:\/\/www.myoncologia.pt\/images\/noticias\/2016_EHA_Fraser_et_al_HELIOS_2Y_FUP_oral_presentation.pdf."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.155986"},{"key":"e_1_2_8_26_1","first-page":"144","article-title":"Prevalence of hypertension and controlled hypertension \u2013 United States","volume":"62","author":"Gillespie C.D.","year":"2013","journal-title":"MMWR Supplements"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23979"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/hon.2441","article-title":"14\u2010ICML Satellite symposia programs and abstracts (updated on May 21 2017)","volume":"35","author":"Celltrion Healthcare","year":"2017","journal-title":"Hematological Oncology"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.122"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_8_31_1","article-title":"Ibrutinib\u2010associated rash: a single\u2010centre experience of clinicopathological features and management","author":"Iberri D.J.","year":"2016","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2017.6976"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14660"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.247"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezw313"},{"key":"e_1_2_8_36_1","first-page":"1949","article-title":"Quinine\u2010induced thrombocytopenia","volume":"32","author":"Lefkowitz J.M.","year":"1986","journal-title":"Canadian Family Physician"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583294"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.12.001"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12107"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/08037051.2014.868629"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23775"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multi\u2010center study of 683 patients","volume":"28","author":"Mato A.R.","year":"2017","journal-title":"Annals of Oncology"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21349"},{"key":"e_1_2_8_45_1","first-page":"1","article-title":"Ibrutinib in previously treated chronic lymphocytic leukemia: updated efficacy and safety of the resonate study with up to four years of follow\u2010up","volume":"102","author":"Moreno C.","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.071"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14321"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.898758"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V124.21.327.327","article-title":"Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the Phase II RESONATE\u2122\u201017 trial","volume":"124","author":"O'Brien S.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"e_1_2_8_51_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood.V128.22.233.233","article-title":"Five\u2010year experience with single\u2010agent ibrutinib in patients with previously untreated and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic leukemia","volume":"128","author":"O'Brien S.M.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_52_1","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood.V126.23.2935.2935","article-title":"Ibrutinib therapy for chronic lymphocytic leukemia (CLL): an analysis of a large cohort of patients treated in routine clinical practice","volume":"126","author":"Parikh S.A.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12468"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.273"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1257795"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13651"},{"key":"e_1_2_8_58_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdw547","article-title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force","volume":"28","author":"Stauder R.","year":"2016","journal-title":"Annals of Oncology"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639203"},{"key":"e_1_2_8_60_1","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1182\/blood.V128.22.3242.3242","article-title":"The impact of atrial fibrillation on subsequent survival of patients receiving ibrutinib as treatment of chronic lymphocytic leukemia (CLL): an international study","volume":"128","author":"Thompson P.A.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147900"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.138289"},{"key":"e_1_2_8_63_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single\u2010centre, open\u2010label, phase 2 trial","volume":"17","author":"Wang M.L.","year":"2017","journal-title":"The Lancet Oncology"},{"key":"e_1_2_8_64_1","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood.V128.22.2040.2040","article-title":"Management and outcomes of atrial fibrillation in patients receiving ibrutinib for hematologic malignancies at a single center","volume":"128","author":"Wiczer T.E.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0030"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144576"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-693598"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"e_1_2_8_69_1","first-page":"Abstract P222","article-title":"French patients with 17p deletion or relapsed\/refractory chronic lymphocytic leukemia included in a temporary authorization for use (ATU) program, presented at the Congress of the Association, Copenhagen, European Hematology & Denmark, June 9\u201312, 2016","volume":"101","author":"Ysebaert L.","year":"2016","journal-title":"Haematologica"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.419"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15080","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T03:54:54Z","timestamp":1695614094000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/bjh.15080"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15080","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,9]]},"assertion":[{"value":"2017-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}